[HTML][HTML] SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
GA Poland, IG Ovsyannikova, RB Kennedy - The Lancet, 2020 - thelancet.com
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is
crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such …
crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such …
[HTML][HTML] Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines
There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical
trials throughout the world. The various candidates employ a range of vaccine strategies …
trials throughout the world. The various candidates employ a range of vaccine strategies …
[HTML][HTML] COVID-19 vaccine design: the Janus face of immune enhancement
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines
identified cellular immunopathology and antibody-dependent enhancement as potential …
identified cellular immunopathology and antibody-dependent enhancement as potential …
[HTML][HTML] SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and
scientific expertise toward the goal of developing investigational vaccines to prevent COVID …
scientific expertise toward the goal of developing investigational vaccines to prevent COVID …
[HTML][HTML] Immunity to SARS-CoV-2: lessons learned
J Fergie, A Srivastava - Frontiers in immunology, 2021 - frontiersin.org
In the year since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and with understanding of the etiology of the coronavirus disease 2019 (COVID-19) …
CoV-2) and with understanding of the etiology of the coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Will SARS-CoV-2 variants of concern affect the promise of vaccines?
RK Gupta - Nature Reviews Immunology, 2021 - nature.com
Initial optimism regarding the development of COVID-19 vaccines has been tempered by the
emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the …
emergence of new variants of SARS-CoV-2. Will vaccination be able to contain the …
[HTML][HTML] The immunology of SARS-CoV-2 infections and vaccines
L Grigoryan, B Pulendran - Seminars in immunology, 2020 - Elsevier
Abstract SARS-CoV-2, the virus that causes COVID-19, emerged in late 2019, and was
declared a global pandemic on March 11th 2020. With over 50 million cases and 1.2 million …
declared a global pandemic on March 11th 2020. With over 50 million cases and 1.2 million …
[PDF][PDF] Approaches and challenges in SARS-CoV-2 vaccine development
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster …
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster …
[HTML][HTML] What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
SARS-CoV-2 vaccines: where are we now?
The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by
using vaccination to generate widespread immunity. The urgent need to develop safe and …
using vaccination to generate widespread immunity. The urgent need to develop safe and …